Who is sponsoring NCT00690092?

NCT00690092 is sponsored by Nielsen BioSciences, Inc..

What condition does NCT00690092 study?

NCT00690092 studies Coccidioidomycosis.

What drugs are being tested in NCT00690092?

Interventions: Spherule-derived coccidioidin.

What is the status of NCT00690092?

NCT00690092 is currently COMPLETED.

Last reviewed 2013-10-28 · How we verify

Safety, Sensitivity and Specificity of Spherule-derived Coccidioidin in Naive Adults, in Adults With a History of Pulmonary Coccidioidomycosis and in Adults With a History of Pulmonary Histoplasmosis

NCT00690092 Phase 3 COMPLETED

Adult volunteers were skin tested with 1.27 ug spherule-derived coccidioidin. The skin test antigen was evaluated in three different populations of adult volunteers to determine the safety and efficacy of the product in the assessment of delayed-type hypersensitivity to Coccidioides immitis. Induration greater than or equal to 5 mm after 48 hours was considered positive for exposure to C. immitis.

Details

Lead sponsor	Nielsen BioSciences, Inc.
Phase	Phase 3
Status	COMPLETED
Enrolment	113
Start date	2005-05
Completion	2007-09

Conditions

Coccidioidomycosis

Interventions

Spherule-derived coccidioidin

Primary outcomes

To determine the ability of spherule-derived coccidioidin to detect cellular hypersensitivity to C. immitis by a positive DTH skin test in a population with a history of pulmonary coccidioidomycosis. — 48 hours

Countries

United States